FDA Accepts for Review Libtayo (cemiplimab-rwlc) in Combination with Chemotherapy for First-line…
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for PD-1…
Read More...
Read More...
